<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322331</url>
  </required_header>
  <id_info>
    <org_study_id>IO Panel</org_study_id>
    <nct_id>NCT04322331</nct_id>
  </id_info>
  <brief_title>Tumor Immune Mechanism of Axillary Lymph Node Metastasis in Early Luminal Type A Breast Cancer</brief_title>
  <official_title>The Different Transcriptional Characterization Of The Tumor Immune Microenvironment of Luminal A Breast Cancer With Different Lymph Node Metastasas Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Luminal type A breast cancer is a type with good clinical prognosis, and the proportion of
      lymph node metastasis is low, but a small number of patients have more lymph node metastasis
      when the primary tumor is very small, and the survival is poor, suggesting that this part of
      Luminal A breast cancer has the different expression of some genes from that of general
      Luminal A breast cancer, which affects tumor invasion and participates in the occurrence of
      tumor metastasis. But the mechanism is not clear, especially in the current tumor
      microenvironment and immune related mechanisms.We want to investigated the relationship of
      the transcriptional tumor immune microenvironment with early lymph node metastasis among
      Luminal A type breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Transcriptional Characterization</measure>
    <time_frame>2020-12</time_frame>
    <description>the relationship of the transcriptional tumor immune microenvironment with lymph node metastases in Luminal A breast tumor;Differences in RNA copy numbers of different genes （using IO Panel） between the two groups of patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">120</enrollment>
  <condition>Immune Microenvironment</condition>
  <condition>Luminal A</condition>
  <condition>Lymph Node Metastases</condition>
  <arm_group>
    <arm_group_label>T1N+</arm_group_label>
    <description>T1 tumor with positive lymph node,N1/N2/N3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2/T3N0</arm_group_label>
    <description>T2/T3 tumor with negative lymph node</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>no intervention</description>
    <arm_group_label>T1N+</arm_group_label>
    <arm_group_label>T2/T3N0</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        invasive breast cancer patients with Luminal A type. Stage T1N1/T1N2/T1N3 are in group 1;
        stage T2N0/T3N0 are in group 2
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  invasive breast cancer with Luminal A type;T1 with positive lymph node or T2/T3 with
             negative lymph node

        Exclusion Criteria:

          -  Missing specimen
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking university people's hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Study Protocol</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

